Pure Global
NCT06364826

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

Gemcitabine, Sintilimab, Bevacizumab Plus IMRT in Patients With Cisplatin Ineligible Locoregionally Advanced Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Nasopharyngeal Carcinoma
Drug/Device/Intervention
Sintilimab, bevacizumab, gemcitabine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Zhejiang Cancer Hospital
Timeline & enrollment
Phase
Phase 2
Start date
Apr 22, 2024
End date
Apr 22, 2026
Enrollment
60 participants
Primary outcome

3-year Event-free survival rate

Summary

This is a prospective, single-center, single-arm, phase II clinical study. The study was
 intended to include patients with locoregionally advanced nasopharyngeal cancer identified by
 histology or cytology, who signed informed consent and met the screening criteria to enter
 the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine,
 Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued
 after radiotherapy until disease progression, intolerable toxicity, death, or the subject's
 decision to withdraw from the study, with a total treatment period of no more than 12 cycles.

ICD-10 classifications
Malignant neoplasm of nasopharynxMalignant neoplasm: Nasopharynx, unspecifiedMalignant neoplasm: Overlapping lesion of nasopharynxBenign neoplasm: NasopharynxMalignant neoplasm: Posterior wall of nasopharynx
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06364826
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06364826 through Pure Global AI's free database. This Phase 2 trial is sponsored by Zhejiang Cancer Hospital and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.